The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial
Abstract
Objective: Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks. Methods: Using 2:1 randomization, 439 PPMS patients received two 1,000mg intravenous rituximab or placebo infusions every 24 weeks, through 96 weeks (4 courses). The primary endpoint was time to confirmed disease progression (CDP), a prespecified increase in Expanded Disability Status Scale sustained for 12 weeks. Secondary endpoints were change from baseline to week 96 in T2 lesion volume and total brain volume on magnetic resonance imaging scans. Results: Differences in time to CDP between rituximab and placebo did not reach significance (96‐week rates: 38.5% placebo, 30.2% rituximab; p = 0.14). From baseline to week 96, rituximab patients had less ( p < 0.001) increase in T2 lesion volume; brain volume change was similar ( p = 0.62) to placebo. Subgroup analysis showed time to CDP was delayed in rituximab‐treated patients aged <51 years (hazard ratio [HR] = 0.52; p = 0.010), those with gadolinium‐enhancing lesions (HR = 0.41; p = 0.007), and those aged <51 years with gadolinium‐enhancing lesions (HR = 0.33; p = 0.009) compared with placebo. Adverse events were comparable between groups; 16.1% of rituximab and 13.6% of placebo patients reported serious events. Serious infections occurred in 4.5% of rituximab and <1.0% of placebo patients. Infusion‐related events, predominantly mild to moderate, were more common with rituximab during the first course, and decreased to rates comparable to placebo on successive courses. Interpretation: Although time to CDP between groups was not significant, overall subgroup analyses suggest selective B‐cell depletion may affect disease progression in younger patients, particularly those with inflammatory lesions. Ann Neurol 2009;66:460–471
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Identification of autoantibodies associated with myelin damage in multiple sclerosis
Genain, C. P., Cannella, B., Hauser, S. L., & Raine, C. S. (1999) · Nature Medicine · doi:10.1038/5532 · Cited by 892
Self-citationPrimary-progressive multiple sclerosis
Miller, D. H., & Leary, S. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70243-0 · Cited by 818
Godbout, J. P., Chen, J., Abraham, J., Richwine, A. F., Berg, B. M., Kelley, K. W., & Johnson, R. W. (2005) · The FASEB Journal · doi:10.1096/fj.05-3776fje · Cited by 813
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 776
Self-citationRituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Self-citationKappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H.-P., Miller, D. H., Montalbán, X., Barkhof, F., Radü, E.-W., Bauer, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61194-5 · Cited by 502
Self-citationWolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21079 · Cited by 429
Self-citationPathogenesis of axonal and neuronal damage in multiple sclerosis
Dutta, R., & Trapp, B. D. (2007) · Neurology · doi:10.1212/01.wnl.0000275229.13012.32 · Cited by 412
Chen, J., Buchanan, J. B., Sparkman, N. L., Godbout, J. P., Freund, G. G., & Johnson, R. W. (2008) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.08.014 · Cited by 398
Link, H., & Huang, Y.-M. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.07.006 · Cited by 396
Lipid microarrays identify key mediators of autoimmune brain inflammation
Kanter, J. L., Narayana, S., Ho, P. P., Catz, I., Warren, K. G., Sobel, R. A., Steinman, L., & Robinson, W. H. (2006) · Nature Medicine · doi:10.1038/nm1344 · Cited by 317
Lyons, J.-A., San, M., Happ, M. P., & Cross, A. H. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199911)29:11<3432::aid-immu3432>3.0.co;2-2 · Cited by 292
Interferon β-1a in primary progressive MS: An exploratory, randomized, controlled trial
Leary, S. M., Miller, D. H., Stevenson, V. L., Brex, P. A., Chard, D. T., & Thompson, A. J. (2003) · Neurology · doi:10.1212/wnl.60.1.44 · Cited by 251
Aging of the immune system: A risk factor for autoimmunity?
Prelog, M. (2006) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.09.008 · Cited by 219
IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event
CHAMPIONS Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000200778.65597.ae · Cited by 203
IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event
Goodin, D. S. (2006) · Neurology · doi:10.1212/01.wnl.0000240402.04846.6d · Cited by 186
Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein
O’Connor, K. C., Appel, H., Bregoli, L., Call, M. E., Catz, I., Chan, J. A., Moore, N. H., Warren, K. G., Wong, S. J., Hafler, D. A., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1974 · Cited by 168
Architectural changes in the thymus of aging mice
Aw, D., Silva, A. B., Maddick, M., Von Zglinicki, T., & Palmer, D. B. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2007.00365.x · Cited by 132
Predicting progression in primary progressive multiple sclerosis: A 10‐year multicenter study
Khaleeli, Z., Ciccarelli, O., Manfredonia, F., Barkhof, F., Brochet, B., Cercignani, M., Dousset, V., Filippi, M., Montalbán, X., Polman, C. H., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21375 · Cited by 111
O’Connor, K. C., Chitnis, T., Griffin, D. E., Piyasirisilp, S., Bar‐Or, A., Khoury, S. J., Wucherpfennig, K. W., & Hafler, D. A. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00002-x · Cited by 101
Immune receptor signaling, aging, and autoimmunity
Hasler, P., & Zouali, M. (2005) · Cellular Immunology · doi:10.1016/j.cellimm.2005.04.012 · Cited by 93
Clinical predictors of early second event in patients with clinically isolated syndrome
Mowry, E. M., Pesic, M., Grimes, B. A., Deen, S. R., Bacchetti, P., & Waubant, E. L. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5063-0 · Cited by 85
Self-citationThe B cell response in multiple sclerosis
Owens, G. P., Bennett, J. L., Gilden, D. H., & Burgoon, M. P. (2006) · Neurological Research · doi:10.1179/016164106x98099 · Cited by 83
Sawada, M., Sawada, H., & Nagatsu, T. (2008) · Neurodegenerative Diseases · doi:10.1159/000113717 · Cited by 78
Is inflammation important in early PPMS? a longitudinal MRI study
Ingle, G. T. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.036590 · Cited by 66
Overview of European pilot study of interferon b-1b in primary progressive multiple sclerosis
Montalbán, X. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1033oa · Cited by 57
The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair?
Pender, M. P. (2004) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2003.12.013 · Cited by 43
Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS
Sid�n, �. (1979) · Journal of Neurology · doi:10.1007/bf00313168 · Cited by 17
Combined diffusion weighting and CSF suppression in functional MRI
Knutsson, L., Bolling, M., Wirestam, R., Holtås, S., & Ståhlberg, F. (2002) · NMR in Biomedicine · doi:10.1002/nbm.767 · Cited by 16
Cited by
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationNew Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Self-citationFilippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Metadata
- Authors
- Hawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., Zhang, J., Chin, P., Smith, C. H., & OLYMPUS trial group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-10
- Volume
- 66
- Issue
- 4
- Pages
- 460-471
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2107008240
- Cited by
- 934
- References
- 34
- FWCI
- 31.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.